Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat

Reuters02-23 21:55

<a href="https://laohu8.com/S/ANIX">Anixa Biosciences</a> to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat

Anixa Biosciences said Duke University School of Medicine immunology professor Jose Conejo-Garcia, co-inventor of its FSHR-mediated CAR-T technology, will deliver a keynote at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026, including discussion of Anixa’s ongoing Phase 1 trial of liraltagene autoleucel (lira-cel). Event-related links: https://edge.prnewswire.com/c/link/?t=0&l=en&o=4624432-1&h=709161843&u=https%3A%2F%2Fwww.anixa.com%2F&a=Anixa+Biosciences%2C+Inc. ; http://ClinicalTrials.gov ; https://edge.prnewswire.com/c/link/?t=0&l=en&o=4624432-1&h=701050431&u=http%3A%2F%2Fwww.anixa.com%2F&a=www.anixa.com

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602230855PR_NEWS_USPR_____LA92767) on February 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613787928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613787928","market":"us","top_or_hot":-1,"title":"Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences said Duke University School of Medicine immunology professor Jose Conejo-Garcia, co-inventor of its FSHR-mediated CAR-T technology, will deliver a keynote at the South Carolina Clinical &amp; Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026, including discussion of Anixa’s ongoing Phase 1 trial of liraltagene autoleucel (lira-cel). Event-related links: https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4624432-1&amp;h=709161843&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc. ; http://ClinicalTrials.gov ; https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4624432-1&amp;h=701050431&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=www.anixa.com\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602230855PR_NEWS_USPR_____LA92767) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-23 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences said Duke University School of Medicine immunology professor Jose Conejo-Garcia, co-inventor of its FSHR-mediated CAR-T technology, will deliver a keynote at the South Carolina Clinical &amp; Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026, including discussion of Anixa’s ongoing Phase 1 trial of liraltagene autoleucel (lira-cel). Event-related links: https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4624432-1&amp;h=709161843&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc. ; http://ClinicalTrials.gov ; https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4624432-1&amp;h=701050431&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=www.anixa.com\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602230855PR_NEWS_USPR_____LA92767) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIX","symbol_name":"Anixa Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL6dqHXq:1","article_id":"2613787928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613787928","pubTimestamp":1771854915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"t=0&l=en&o=4624432-1&h=701050431&u=http%3A%2F%2Fwww.anixa.com%2F&a=www.anixa.com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIX":"Anixa Biosciences","BK7035":"电影和娱乐","BK4139":"生物科技","EVT.AU":"EVT Ltd","CLDX":"塞德斯医疗"},"translate_title":"Anixa Biosciences将在SCTR研究所2026年务虚会上重点关注LIRA-cel 1期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVT.AU":0.9,"CLDX":0.9,"ANIX":0.9},"content_text":"Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat\n    \n\n        Anixa Biosciences said Duke University School of Medicine immunology professor Jose Conejo-Garcia, co-inventor of its FSHR-mediated CAR-T technology, will deliver a keynote at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026, including discussion of Anixa’s ongoing Phase 1 trial of liraltagene autoleucel (lira-cel). Event-related links: https://edge.prnewswire.com/c/link/?t=0&l=en&o=4624432-1&h=709161843&u=https%3A%2F%2Fwww.anixa.com%2F&a=Anixa+Biosciences%2C+Inc. ; http://ClinicalTrials.gov ; https://edge.prnewswire.com/c/link/?t=0&l=en&o=4624432-1&h=701050431&u=http%3A%2F%2Fwww.anixa.com%2F&a=www.anixa.com\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602230855PR_NEWS_USPR_____LA92767) on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613787928","isCrawlerRequest":true}